Resultaterne fra en metaanalyse af 13 kliniske studier med data fra mere end 3800 patienter, som er blevet behandlet med capecitabin, viste at i alle studier kombineret, var stigende alder (ved 10- års forøgelse) statistisk signifikant associeret med en øget risiko for udviklingen af hand- foot syndrom og diarré og med en faldende risiko for at udvikle neutropeni.
The results of a meta-analysis of 13 clinical trials with data from over 3800 patients treated with capecitabine showed that in all studies combined, increasing age (by 10 year increments) was statistically significantly associated with an increased risk of developing HFS and diarrhea and with a decreased risk of developing neutropenia.